Cell Reports Medicine (@cp-cellrepmed.bsky.social)

Online now: A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer

loading . . .

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer Advanced pancreatic cancer lacks effective, well-tolerated options beyond chemotherapy. Shi et al. demonstrate that IAP antagonist APG-1387 combined with nab-paclitaxel and gemcitabine (AG) exhibits manageable safety without potentiating AG toxicity and demonstrates encouraging antitumor activity in AG-naive/resistant patients. APG-1387 monotherapy shows potential to maintain disease control in AG-intolerant cases. http://dlvr.it/TNHQdc